On May 8, 2018, WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, completed its A-share initial public offering and listing on the Shanghai Stock Exchange. The company issued 104,198,600 shares of common stock in the IPO at a public offering price of RMB21.60 per share. WuXi AppTec's IPO is the first China-based unicorn company to be listed domestically through an A-share offering. Wilson Sonsini acted as the lead international counsel to WuXi AppTec in the public offering and related restructuring. Wilson Sonsini also advised the buyer consortium in the privatization and delisting from the New York Stock Exchange in 2015 of WuXi PharmaTech (Cayman) Inc., WuXi AppTec's predecessor, and the issuer in the spinoff IPO on the Stock Exchange of Hong Kong in 2017 of WuXi Biologics (Cayman) Inc., a former subsidiary of WuXi PharmaTech.

The Wilson Sonsini team that advised WuXi AppTec includes:

China Team:
Weiheng Chen, Partner
Jie Zhu, Partner
Linyan (Jill) Sheng, Associate
Draco Ng, Counsel

U.S. Team:
Barry Taylor, Partner

For more information, please see WuXi AppTec's press release.